Add to my selection

XULTOPHY (insuline degludec/liraglutide), antidiabétique

Medicine - Posted on Aug 26 2021

Active substance (DCI)

insuline dégludec
liraglutide
insuline degludec

history (4)

7/21/21

XULTOPHY (insuline dégludec / liraglutide)

Key points The Committee reassessed nine proprietary medicinal products, including two fixed-dose combinations with insulins...

CAV :
54321

icône flèche
12/6/17

XULTOPHY (insulin degludec/liraglutide), antidiabetic

Substantial clinical benefit in patients with type 2 diabetes but no clinical added value demonstrated in case of failure of...

CAV :
54321

icône flèche
4/5/17

XULTOPHY (insulin degludec/liraglutide), antidiabetic

Insufficient actual benefit in the treatment of patients with type 2 diabetes not sufficiently controlled by a GLP-1 analogu...

CAV :
54321

icône flèche
1/20/16

XULTOPHY (insulin degludec/liraglutide), antidiabetic

No clinical benefit demonstrated in type 2 diabetics whose treatment is optimised with metformin + basal insulin + liragluti...

CAV :
54321

icône flèche

Technical information

ATC code

A10AE56

Manufacturer

NOVO NORDISK

Presentation

XULTOPHY 100 unités/ml + 3,6 mg/ml, solution injectable (code CIS : 60480810)

5 cartouche(s) en verre de 3 ml dans stylo pré-rempli - Code CIP : 3400930018514

All our publications

Autoimmune diseases

Diabetes mellitus